Scudla V, Bacovský J, Budíková M, Srovnalík K, Kubalová D
III. interní klinika LF UP a FN, Olomouc.
Vnitr Lek. 1995 Sep;41(9):599-604.
In a group of 111 subjects with multiple myeloma (MM) comprising a group of 34 patients examined when the diagnosis was established and a group of 77 patients examined in different stages of development of MM the authors evaluated the relationship between interleukin-6 (IL-6) serum levels and the clinical activity and the stage of the disease. In both groups a significant relationship was found between IL-6 and the clinical activity of MM; "stable" and "active" stages of the disease differed by the frequency of elevated values and the level of IL-6. In both groups the authors recorded rising levels and a rising rate of subjects with elevated IL-6 levels with advancing stages of the disease. When staging systems were used according to Durie-Salmon, the British Medical Research Council and according to Bataille the highest IL-6 values were recorded in the third stage of the disease, these values being significantly higher than in stages 1 and 2. In the group assembled at the time of assessment of the diagnosis of MM the described differences did not reach (with the exception of the evaluation according to Bataille) statistical significance. The classification of patients in stages 1-3 into sub-groups with regard to the activity of the disease ("stable" and "active") was associated with significantly different IL-6 levels. The investigation revealed that examination of IL-6 levels contributes at present rather to the understanding of the pathogenesis and biology of MM than to practical evaluation of the severity, activity and stage of the disease.
在一组111例多发性骨髓瘤（MM）患者中，包括34例确诊时接受检查的患者和77例处于MM不同发展阶段接受检查的患者，作者评估了白细胞介素-6（IL-6）血清水平与疾病临床活动及分期之间的关系。在两组中均发现IL-6与MM的临床活动之间存在显著关系；疾病的“稳定”和“活动”阶段在IL-6值升高的频率和水平上存在差异。在两组中，作者都记录到随着疾病进展，IL-6水平升高的患者数量及其升高速率也在增加。当根据Durie-Salmon分期系统、英国医学研究委员会分期系统以及Bataille分期系统进行分期时，疾病第三期的IL-6值最高，这些值显著高于第一期和第二期。在MM诊断评估时收集的组中，所述差异（根据Bataille评估除外）未达到统计学意义。根据疾病活动度（“稳定”和“活动”）将1-3期患者分为亚组与显著不同的IL-6水平相关。研究表明，目前检测IL-6水平更多地有助于理解MM的发病机制和生物学特性，而非对疾病严重程度、活动度及分期进行实际评估。
